logo of the EU drugs agency

You are viewing archived content

Please note that this page is a static copy of a previously published web page and is no longer actively maintained.
Be aware that the information contained here may be out-of-date.
For the most recent information, we recommend visiting the main website of the EMCDDA.

Treatment demand indicator (TDI)

Statistics found here the category is Demand for treatment for drug use (TDI)

Category Title
TDI TDI-1. Trend in estimated number of new clients entering treatment by primary drug used, from 2004 to 2009 Part (i) Percentage distribution by primary drug
TDI TDI-1. Trend in estimated number of new clients entering treatment by primary drug used, from 2004 to 2009 Part (ii) Numbers of clients by primary drug
TDI TDI-2. New and all clients entering treatment by primary drug: heroin, cocaine, cannabis, other stimulants, other drugs in 2009. Part (i) New clients
TDI TDI-2. New and all clients entering treatment by primary drug: heroin, cocaine, cannabis, other stimulants, other drugs in 2009 in all EU Member States Part (ii) All clients
TDI TDI-3. Trend in estimated number of all clients entering treatment by primary drug used, from 2004 to 2009 Part (i) Percentage distribution by primary drug
TDI TDI-3. Trend in estimated number of all clients entering treatment by primary drug used, from 2004 to 2009 Part (ii) Numbers of clients by primary drug
TDI TDI-7. New outpatient clients injecting opioid as primary drug from 2004 to 2009 in 15 countries supplying data
TDI TDI-0. Data sources for clients entering treatment
TDI TDI-1. Clients entering treatment and treatment units by country, 2009 or most recent year available
TDI TDI-2. Clients entering treatment and reporting treatment units, 1998 to 2009 Part (i) New clients by country and year of treatment
TDI TDI-2. Clients entering treatment and reporting treatment units, 1998 to 2009 Part (ii) All clients by country and year of treatment
TDI TDI-2. Clients entering treatment and reporting treatment units, 1998 to 2009 Part (iii) Reporting treatment units by country and year of treatment
TDI TDI-2. Clients entering treatment and reporting treatment units, 1998 to 2009 Part (iv) Types of reporting treatment unit by country
TDI TDI-3. New clients entering treatment by primary drug, 1998 to 2009 Part (i) New heroin clients by country and year of treatment (%)
TDI TDI-3. New clients entering treatment by primary drug, 1998 to 2009 Part (ii) New cocaine clients by country and year of treatment (%)
TDI TDI-3. New clients entering treatment by primary drug, 1998 to 2009 Part (iii) New stimulants (amphetamines and MDMA) clients by country and year of treatment (%)
TDI TDI-3. New clients entering treatment by primary drug, 1998 to 2009 Part (iv) New cannabis clients by country and year of treatment (%)
TDI TDI-4. Demographic characteristics of clients entering treatment, 2009 or most recent year available Part (i) New clients by country and gender (%)
TDI TDI-4. Demographic characteristics of clients entering treatment, 2009 or most recent year available Part (ii) All clients by country and gender (%)
TDI TDI-4. Demographic characteristics of clients entering treatment, 2009 or most recent year available Part (iii) New clients by country and age (%)
TDI TDI-4. Demographic characteristics of clients entering treatment, 2009 or most recent year available Part (iv) All clients by country and age (%)
TDI TDI-5. Primary drug and rates of injection of primary drug of clients entering treatment, 2009 or most recent year available Part (i) New clients by country and primary drug (%), regardless whether they inject the drug
TDI TDI-5. Primary drug and rates of injection of primary drug of clients entering treatment, 2009 or most recent year available Part (ii) All clients by country and primary drug (%), regardless whether they inject the drug
TDI TDI-5. Primary drug and rates of injection of primary drug of clients entering treatment, 2009 or most recent year available Part (iii) New clients by country and rates of injection of primary drug (%)
TDI TDI-5. Primary drug and rates of injection of primary drug of clients entering treatment, 2009 or most recent year available Part (iv) All clients by country and rates of injection of primary drug (%)
TDI TDI-6. Incidence of treatment demand for drug use, 2009 or most recent year available. New clients by country (rate per 100 000 population aged 15 to 64 years old)
TDI TDI-7. Data coverage, 2009 or most recent year available Part (i) Clients entering treatment by country and type of treatment centre and type of client
TDI TDI-7. Data coverage, 2009 or most recent year available Part (ii) Units by country and type of treatment centre and reporting status
TDI TDI-8. Primary use of stimulants of clients entering treatment, 2009 or most recent year available Part (i) New clients by country and type of stimulant (%)
TDI TDI-8. Primary use of stimulants of clients entering treatment, 2009 or most recent year available Part (ii) All clients by country and type of stimulant (%)
TDI TDI-9. Demographic characteristics of clients entering outpatient treatment, 2009 or most recent year available Part (i) New outpatient clients by country and gender
TDI TDI-9. Demographic characteristics of clients entering outpatient treatment, 2009 or most recent year available Part (ii) All outpatient clients by country and by gender
TDI TDI-9. Demographic characteristics of clients entering outpatient treatment, 2009 or most recent year available Part (iii) New outpatient clients by country and age
TDI TDI-9. Demographic characteristics of clients entering outpatient treatment, 2009 or most recent year available Part (iv) All outpatient clients by country and age
TDI TDI-10. Age distributions and primary drug distributions — EU summary of clients entering treatment, 2009 or most recent year available Part (i) New outpatient clients, age distribution by primary drug (%)
TDI TDI-10. Age distributions and primary drug distributions — EU summary of clients entering treatment, 2009 or most recent year available Part (ii) New outpatient clients, primary drug distribution by age (%)
TDI TDI-10. Age distributions and primary drug distributions — EU summary of clients entering treatment, 2009 or most recent year available Part (iii) All outpatient clients, age distribution by primary drug (%)
TDI TDI-10. Age distributions and primary drug distributions — EU summary of clients entering treatment, 2009 or most recent year available Part (iv) All outpatient clients, primary drug distribution by age (%)
TDI TDI-10. Age distributions and primary drug distributions — EU summary of clients entering treatment, 2009 or most recent year available Part (v) New inpatient clients, age distribution by primary drug (%)
TDI TDI-10. Age distributions and primary drug distributions — EU summary of clients entering treatment, 2009 or most recent year available Part (vi) New inpatient clients, primary drug distribution by age (%)
TDI TDI-10. Age distributions and primary drug distributions — EU summary of clients entering treatment, 2009 or most recent year available Part (vii) All inpatient clients, age distribution by primary drug (%)
TDI TDI-10. Age distributions and primary drug distributions — EU summary of clients entering treatment, 2009 or most recent year available Part (viii) All inpatient clients, primary drug distribution by age (%)
TDI TDI-11. Age at first use distributions and primary drug distributions — EU summary of clients entering treatment, 2009 or most recent year available Part (i) New outpatient clients, age at first use distribution by primary drug (%)
TDI TDI-11. Age at first use distributions and primary drug distributions — EU summary of clients entering treatment, 2009 or most recent year available Part (ii) New outpatient clients, primary drug distribution by age at first use (%)
TDI TDI-11. Age at first use distributions and primary drug distributions — EU summary of clients entering treatment, 2009 or most recent year available Part (iii) All outpatient clients, age at first use distribution by primary drug (%)
TDI TDI-11. Age at first use distributions and primary drug distributions — EU summary of clients entering treatment, 2009 or most recent year available Part (iv) All outpatient clients, primary drug distribution by age at first use (%)
TDI TDI-11. Age at first use distributions and primary drug distributions — EU summary of clients entering treatment, 2009 or most recent year available Part (v) New inpatient clients, age at first use distribution by primary drug (%)
TDI TDI-11. Age at first use distributions and primary drug distributions — EU summary of clients entering treatment, 2009 or most recent year available Part (vi) New inpatient clients, primary drug distribution by age at first use (%)
TDI TDI-11. Age at first use distributions and primary drug distributions — EU summary of clients entering treatment, 2009 or most recent year available Part (vii) All inpatient clients, age at first use distribution by primary drug (%)
TDI TDI-11. Age at first use distributions and primary drug distributions — EU summary of clients entering treatment, 2009 or most recent year available Part (viii) All inpatient clients, primary drug distribution by age at first use (%)
TDI TDI-12. Education status of clients entering treatment, 2009 or most recent year available Part (i) New outpatient clients by country and education status (%)
TDI TDI-12. Education status of clients entering treatment, 2009 or most recent year available Part (ii) All outpatient clients by country and education status (%)
TDI TDI-12. Education status of clients entering treatment, 2009 or most recent year available Part (iii) New inpatient clients by country and education status (%)
TDI TDI-12. Education status of clients entering treatment, 2009 or most recent year available Part (iv) All inpatient clients by country and education status (%)
TDI TDI-13. Labour status of clients entering treatment, 2009 or most recent year available Part (i) New outpatient clients by country and labour status (%)
TDI TDI-13. Labour status of clients entering treatment, 2009 or most recent year available Part (ii) All outpatient clients by country and labour status (%)
TDI TDI-13. Labour status of clients entering treatment, 2009 or most recent year available Part (iii) New inpatient clients by country and labour status (%)
TDI TDI-13. Labour status of clients entering treatment, 2009 or most recent year available Part (iv) All inpatient clients by country and labour status (%)
TDI TDI-14. Persons with whom client is living on entering treatment, 2009 or most recent year available Part (i) New outpatient clients by country and with whom living (%)
TDI TDI-14. Persons with whom client is living on entering treatment, 2009 or most recent year available Part (ii) All outpatient clients by country and with whom living (%)
TDI TDI-14. Persons with whom client is living on entering treatment, 2009 or most recent year available Part (iii) New inpatient clients by country and with whom living (%)
TDI TDI-14. Persons with whom client is living on entering treatment, 2009 or most recent year available Part (iv) All inpatient clients by country and with whom living (%)
TDI TDI-15. Type of accommodation of clients entering treatment, 2009 or most recent year available Part (i) New clients entering outpatient treatment by country and type of accommodation (%)
TDI TDI-15. Type of accommodation of clients entering treatment, 2009 or most recent year available Part (ii) All clients entering outpatient treatment by country and type of accommodation (%)
TDI TDI-15. Type of accommodation of clients entering treatment, 2009 or most recent year available Part (iii) New clients entering inpatient treatment by country and type of accommodation (%)
TDI TDI-15. Type of accommodation of clients entering treatment, 2009 or most recent year available Part (iv) All clients entering inpatient treatment by country and type of accommodation (%)
TDI TDI-16. Source of referral of clients entering treatment, 2009 or most recent year available Part (i) New outpatient clients by country and source of referral (%)
TDI TDI-16. Source of referral of clients entering treatment, 2009 or most recent year available Part (ii) All outpatient clients by country and source of referral (%)
TDI TDI-16. Source of referral of clients entering treatment, 2009 or most recent year available Part (iii) New inpatient clients by country and source of referral (%)
TDI TDI-16. Source of referral of clients entering treatment, 2009 or most recent year available Part (iv) All inpatient clients by country and source of referral (%)
TDI TDI-17. Route of administration by primary drug of clients entering treatment, 2009 or most recent year available Part (i) New opioid outpatient clients by country and usual route of administration (%)
TDI TDI-17. Route of administration by primary drug of clients entering treatment, 2009 or most recent year available Part (ii) All opioid outpatient clients by country and usual route of administration (%)
TDI TDI-17. Route of administration by primary drug of clients entering treatment, 2009 or most recent year available Part (iii) New cocaine (HCl and crack) outpatient clients by country and usual route of administration (%)
TDI TDI-17. Route of administration by primary drug of clients entering treatment, 2009 or most recent year available Part (iv) All cocaine (HCl and crack) outpatient clients by country and usual route of administration (%)
TDI TDI-17. Route of administration by primary drug of clients entering treatment, 2009 or most recent year available Part (v) New stimulants (other than cocaine) outpatient clients by country and usual route of administration (%)
TDI TDI-17. Route of administration by primary drug of clients entering treatment, 2009 or most recent year available Part (vi) All stimulants (other than cocaine) outpatient clients by country and usual route of administration (%)
TDI TDI-17. Route of administration by primary drug of clients entering treatment, 2009 or most recent year available Part (vii) New hypnotics and sedatives outpatient clients by country and usual route of administration (%)
TDI TDI-17. Route of administration by primary drug of clients entering treatment, 2009 or most recent year available Part (viii) All hypnotics and sedatives outpatient clients by country and usual route of administration
TDI TDI-18. Frequency of use of primary drug of clients entering treatment, 2009 or most recent year available Part (i) New outpatient clients by primary drug and frequency of use (%)
TDI TDI-18. Frequency of use of primary drug of clients entering treatment, 2009 or most recent year available Part (ii) All outpatient clients by primary drug and frequency of use (%)
TDI TDI-18. Frequency of use of primary drug of clients entering treatment, 2009 or most recent year available Part (iii) New inpatient clients by primary drug and frequency of use (%)
TDI TDI-18. Frequency of use of primary drug of clients entering treatment, 2009 or most recent year available Part (iv) All inpatient clients by primary drug and frequency of use (%)
TDI TDI-19. Primary drug of clients entering treatment, 2009 or most recent year available Part (i) New outpatient clients by country and primary drug (%)
TDI TDI-19. Primary drug of clients entering treatment, 2009 or most recent year available Part (ii) All outpatient clients by country and primary drug (%)
TDI TDI-19. Primary drug of clients entering treatment, 2009 or most recent year available Part (iii) New inpatient clients by country and primary drug (%)
TDI TDI-19. Primary drug of clients entering treatment, 2009 or most recent year available Part (iv) All inpatient clients by country and primary drug (%)
TDI TDI-21. Gender ratio by primary drug of clients entering treatment, 2009 or most recent year available Part (i) New outpatient clients, ratio of males to females by country and primary drug
TDI TDI-21. Gender ratio by primary drug of clients entering treatment, 2009 or most recent year available Part (ii) All outpatient clients, ratio of males to females by country and primary drug
TDI TDI-21. Gender ratio by primary drug of clients entering treatment, 2009 or most recent year available Part (iii) New inpatient clients, ratio of males to females by country and primary drug
TDI TDI-21. Gender ratio by primary drug of clients entering treatment, 2009 or most recent year available Part (iv) All inpatient clients, ratio of males to females by country and primary drug
TDI TDI-22. Secondary drugs cited by clients entering treatment, 2009 or most recent year available Part (i) Outpatient units
TDI TDI-22. Secondary drugs cited by clients entering treatment, 2009 or most recent year available Part (ii) Inpatient units
TDI TDI-24. Type of treatment centre by primary drug of clients entering treatment, 2009 or most recent year available Part (i) New clients by country and primary drug and type of treatment centre (%)
TDI TDI-24. Type of treatment centre by primary drug of clients entering treatment, 2009 or most recent year available Part (ii) All clients by country and primary drug and type of treatment centre (%)
TDI TDI-25. Age distribution of all clients entering outpatient treatment by primary drug and gender, 2009 or most recent year available
TDI TDI-32. Mean age of clients entering treatment by primary drug and gender, 2009 or most recent year available Part (i) Outpatient clients
TDI TDI-32. Mean age of clients entering treatment by primary drug and gender, 2009 or most recent year available Part (ii) Inpatient clients
TDI TDI-33. Mean age at first use and mean age at entering treatment by gender and primary drug among new clients entering treatment, 2009 or most recent year available Part (i) Outpatient units
TDI TDI-33. Mean age at first use and mean age at entering treatment by gender and primary drug among new clients entering treatment, 2009 or most recent year available Part (ii) Inpatient units
TDI TDI-36. Primary amphetamine use among new clients entering treatment (%), 2003 to 2009
TDI TDI-37. Amphetamines and ecstasy clients entering drug treatment, 2009 or most recent year available Part (i) All clients by country and primary drug and type of treatment unit
TDI TDI-37. Amphetamines and ecstasy clients entering drug treatment, 2009 or most recent year available Part (ii) Outpatient clients by primary drug and mean age, gender ratio
TDI TDI-37. Amphetamines and ecstasy clients entering drug treatment, 2009 or most recent year available Part (iii) Inpatient clients by primary drug and mean age, gender ratio
TDI TDI-37. Amphetamines and ecstasy clients entering drug treatment, 2009 or most recent year available Part (iv) Outpatient clients by secondary drug and primary drug
TDI TDI-37. Amphetamines and ecstasy clients entering drug treatment, 2009 or most recent year available Part (v) Inpatient clients by secondary drug and primary drug
TDI TDI-38. Clients in treatment by primary drug, all types of treatment centre, 2007 or most recent year available Part (i) Number of clients by country, primary drug, and incidence/prevalence
TDI TDI-38. Clients in treatment by primary drug, all types of treatment centre, 2007 or most recent year available Part (ii) Percentage of clients with known primary drug, by country, primary drug and incidence/prevalence
TDI TDI-38. Table TDI-38: Clients in treatment by primary drug, all types of treatment centre, 2007 or most recent year available Part (iii) Percentage of clients injecting their primary drug by country, primary drug and incidence/prevalence
TDI TDI-102. New clients entering outpatient treatment by primary drug and age, 2009 or most recent year available Part (i) New opioid outpatient clients by country and age
TDI TDI-102. New clients entering outpatient treatment by primary drug and age, 2009 or most recent year available Part (ii) New cocaine (HCI and 'crack') outpatient clients by country and age
TDI TDI-102. New clients entering outpatient treatment by primary drug and age, 2009 or most recent year available Part (iii) New stimulants (other than cocaine) outpatient clients by country and age
TDI TDI-102. New clients entering outpatient treatment by primary drug and age, 2009 or most recent year available Part (iv) New hallucinogen outpatient clients by country and age
TDI TDI-102. New clients entering outpatient treatment by primary drug and age, 2009 or most recent year available Part (v) New hypnotics and sedatives outpatient clients by country and age
TDI TDI-102. New clients entering outpatient treatment by primary drug and age, 2009 or most recent year available Part (vi) New volatile inhalant outpatient clients by country and age
TDI TDI-102. New clients entering outpatient treatment by primary drug and age, 2009 or most recent year available Part (vii) New cannabis outpatient clients by country and age
TDI TDI-102. New clients entering outpatient treatment by primary drug and age, 2009 or most recent year available Part (viii) New 'other drugs' outpatient clients by country and by age
TDI TDI-103. All clients entering outpatient treatment by primary drug and age, 2009 or most recent year available Part (i) All opioid outpatient clients by country and age
TDI TDI-103. All clients entering outpatient treatment by primary drug and age, 2009 or most recent year available Part (ii) All cocaine (HCI and 'crack') outpatient clients by country and age
TDI TDI-103. All clients entering outpatient treatment by primary drug and age, 2009 or most recent year available Part (iii) All stimulants (other than cocaine) outpatient clients by country and age
TDI TDI-103. All clients entering outpatient treatment by primary drug and age, 2009 or most recent year available Part (iv) All hallucinogen outpatient clients by country and age
TDI TDI-103. All clients entering outpatient treatment by primary drug and age, 2009 or most recent year available Part (v) All hypnotics and sedatives outpatient clients by country and age
TDI TDI-103. All clients entering outpatient treatment by primary drug and age, 2009 or most recent year available Part (vi) All volatile inhalant outpatient clients by country and age
TDI TDI-103. All clients entering outpatient treatment by primary drug and age, 2009 or most recent year available Part (vii) All cannabis outpatient clients by country and age
TDI TDI-103. All clients entering outpatient treatment by primary drug and age, 2009 or most recent year available Part (viii) All 'other drugs' outpatient clients by country and by age
TDI TDI-104. New clients entering inpatient treatment by primary drug and age, 2009 or most recent year available Part (i) New opioid inpatient clients by country and age
TDI TDI-104. New clients entering inpatient treatment by primary drug and age, 2009 or most recent year available Part (ii) New cocaine (HCI and 'crack') inpatient clients by country and age
TDI TDI-104. New clients entering inpatient treatment by primary drug and age, 2009 or most recent year available Part (iii) New stimulants (other than cocaine) inpatient clients by country and age
TDI TDI-104. New clients entering inpatient treatment by primary drug and age, 2009 or most recent year available Part (iv) New hallucinogen inpatient clients by country and age
TDI TDI-104. New clients entering inpatient treatment by primary drug and age, 2009 or most recent year available Part (v) New hypnotics and sedatives inpatient clients by country and age
TDI TDI-104. New clients entering inpatient treatment by primary drug and age, 2009 or most recent year available Part (vi) New volatile inhalant inpatient clients by country and age
TDI TDI-104. New clients entering inpatient treatment by primary drug and age, 2009 or most recent year available Part (vii) New cannabis inpatient clients by country and age
TDI TDI-104. New clients entering inpatient treatment by primary drug and age, 2009 or most recent year available Part (viii) New 'other drugs' inpatient clients by country and by age
TDI TDI-105. All clients entering inpatient treatment by primary drug and age, 2009 or most recent year available Part (i) All opioid inpatient clients by country and age
TDI TDI-105. All clients entering inpatient treatment by primary drug and age, 2009 or most recent year available Part (ii) All cocaine (HCI and 'crack') inpatient clients by country and age
TDI TDI-105. All clients entering inpatient treatment by primary drug and age, 2009 or most recent year available Part (iii) All stimulants (other than cocaine) inpatient clients by country and age
TDI TDI-105. All clients entering inpatient treatment by primary drug and age, 2009 or most recent year available Part (iv) All hallucinogen inpatient clients by country and age
TDI TDI-105. All clients entering inpatient treatment by primary drug and age, 2009 or most recent year available Part (v) All hypnotics and sedatives inpatient clients by country and age
TDI TDI-105. All clients entering inpatient treatment by primary drug and age, 2009 or most recent year available Part (vi) All volatile inhalant inpatient clients by country and age
TDI TDI-105. All clients entering inpatient treatment by primary drug and age, 2009 or most recent year available Part (vii) All cannabis inpatient clients by country and age
TDI TDI-105. All clients entering inpatient treatment by primary drug and age, 2009 or most recent year available Part (viii) All 'other drugs' inpatient clients by country and by age
TDI TDI-106. New clients entering outpatient treatment by primary drug and age at first use, 2009 or most recent year available Part (i) New opioid outpatient clients by country and age at first use
TDI TDI-106. New clients entering outpatient treatment by primary drug and age at first use, 2009 or most recent year available Part (ii) New cocaine (HCI and 'crack') outpatient clients by country and age at first use
TDI TDI-106. New clients entering outpatient treatment by primary drug and age at first use, 2009 or most recent year available Part (iii) New stimulants (other than cocaine) outpatient clients by country and age at first use
TDI TDI-106. New clients entering outpatient treatment by primary drug and age at first use, 2009 or most recent year available Part (iv) New hallucinogen outpatient clients by country and age at first use
TDI TDI-106. New clients entering outpatient treatment by primary drug and age at first use, 2009 or most recent year available Part (v) New hypnotics and sedatives outpatient clients by country and age at first use
TDI TDI-106. New clients entering outpatient treatment by primary drug and age at first use, 2009 or most recent year available Part (vi) New volatile inhalant outpatient clients by country and age at first use
TDI TDI-106. New clients entering outpatient treatment by primary drug and age at first use, 2009 or most recent year available Part (vii) New cannabis outpatient clients by country and age at first use
TDI TDI-106. New clients entering outpatient treatment by primary drug and age at first use, 2009 or most recent year available Part (viii) New 'other drugs' outpatient clients by country and by age at first use
TDI TDI-107. All clients entering outpatient treatment by primary drug and age at first use, 2009 or most recent year available Part (i) All opioid outpatient clients by country and age at first use
TDI TDI-107. All clients entering outpatient treatment by primary drug and age at first use, 2009 or most recent year available Part (ii) All cocaine (HCI and 'crack') outpatient clients by country and age at first use
TDI TDI-107. All clients entering outpatient treatment by primary drug and age at first use, 2009 or most recent year available Part (iii) All stimulants (other than cocaine) outpatient clients by country and age at first use
TDI TDI-107. All clients entering outpatient treatment by primary drug and age at first use, 2009 or most recent year available Part (iv) All hallucinogen outpatient clients by country and age at first use
TDI TDI-107. All clients entering outpatient treatment by primary drug and age at first use, 2009 or most recent year available Part (v) All hypnotics and sedatives outpatient clients by country and age at first use
TDI TDI-107. All clients entering outpatient treatment by primary drug and age at first use, 2009 or most recent year available Part (vi) All volatile inhalant outpatient clients by country and age at first use
TDI TDI-107. All clients entering outpatient treatment by primary drug and age at first use, 2009 or most recent year available Part (vii) All cannabis outpatient clients by country and age at first use
TDI TDI-107. All clients entering outpatient treatment by primary drug and age at first use, 2009 or most recent year available Part (viii) All 'other drugs' outpatient clients by country and by age at first use
TDI TDI-108. New clients entering inpatient treatment by primary drug and age at first use, 2009 or most recent year available Part (i) New opioid inpatient clients by country and age at first use
TDI TDI-108. New clients entering inpatient treatment by primary drug and age at first use, 2009 or most recent year available Part (ii) New cocaine (HCI and 'crack') inpatient clients by country and age at first use
TDI TDI-108. New clients entering inpatient treatment by primary drug and age at first use, 2009 or most recent year available Part (iii) New stimulants (other than cocaine) inpatient clients by country and age at first use
TDI TDI-108. New clients entering inpatient treatment by primary drug and age at first use, 2009 or most recent year available Part (iv) Number of clients using hallucinogens as primary drug
TDI TDI-108. New clients entering inpatient treatment by primary drug and age at first use, 2009 or most recent year available Part (v) New hypnotics and sedatives inpatient clients by country and age at first use
TDI TDI-108. New clients entering inpatient treatment by primary drug and age at first use, 2009 or most recent year available Part (vi) New volatile inhalant inpatient clients by country and age at first use
TDI TDI-108. New clients entering inpatient treatment by primary drug and age at first use, 2009 or most recent year available Part (vii) New cannabis inpatient clients by country and age at first use
TDI TDI-108. New clients entering inpatient treatment by primary drug and age at first use, 2009 or most recent year available Part (viii) New 'other drugs' inpatient clients by country and age at first use
TDI TDI-109. All clients entering inpatient treatment by primary drug and age at first use, 2009 or most recent year available Part (i) All opioid inpatient clients by country and age at first
TDI TDI-109. All clients entering inpatient treatment by primary drug and age at first use, 2009 or most recent year available Part (ii) All cocaine (HCI and 'crack') inpatient clients by country and age at first use
TDI TDI-109. All clients entering inpatient treatment by primary drug and age at first use, 2009 or most recent year available Part (iii) All stimulants (other than cocaine) inpatient clients by country and age at first use
TDI TDI-109. All clients entering inpatient treatment by primary drug and age at first use, 2009 or most recent year available Part (iv) All hallucinogen inpatient clients by country and age at first use
TDI TDI-109. All clients entering inpatient treatment by primary drug and age at first use, 2009 or most recent year available Part (v) All hypnotics and sedatives inpatient clients by country and age at first use
TDI TDI-109. All clients entering inpatient treatment by primary drug and age at first use, 2009 or most recent year available Part (vi) All volatile inhalant inpatient clients by country and age at first use
TDI TDI-109. All clients entering inpatient treatment by primary drug and age at first use, 2009 or most recent year available Part (vii) All cannabis inpatient clients by country and age at first use
TDI TDI-109. All clients entering inpatient treatment by primary drug and age at first use, 2009 or most recent year available Part (viii) All 'other drugs' inpatient clients by country and by age at first use
TDI TDI-111. Frequency of use of primary drug of clients entering outpatient treatment, 2009 or most recent year available Part (i) New opioid outpatient clients by country and frequency of use (%)
TDI TDI-111. Frequency of use of primary drug of clients entering outpatient treatment, 2009 or most recent year available Part (ii) All opioid outpatient clients by country and frequency of use (%)
TDI TDI-111. Frequency of use of primary drug of clients entering outpatient treatment, 2009 or most recent year available Part (iii) New cocaine (HCI and ‘crack’) outpatient clients by country and frequency of use (%)
TDI TDI-111. Frequency of use of primary drug of clients entering outpatient treatment, 2009 or most recent year available Part (iv) All cocaine (HCI and ‘crack’) outpatient clients by country and frequency of use (%)
TDI TDI-111. Frequency of use of primary drug of clients entering outpatient treatment, 2009 or most recent year available Part (v) New stimulants (other than cocaine) outpatient clients by country and frequency of use (%)
TDI TDI-111. Frequency of use of primary drug of clients entering outpatient treatment, 2009 or most recent year available Part (vi) All stimulants (other than cocaine) outpatient clients by country and frequency of use (%)
TDI TDI-111. All clients entering outpatient treatment by primary drug and age at first use, 2009 or most recent year available Part (vii) New cannabis outpatient clients by country and frequency of use (%)
TDI TDI-111. Frequency of use of primary drug of clients entering outpatient treatment, 2009 or most recent year available Part (viii) All cannabis outpatient clients by country and frequency of use (%)
TDI TDI-112. Frequency of use of primary drug of clients entering inpatient treatment, 2009 or most recent year available Part (i) New opioid inpatient clients by country and frequency of use (%)
TDI TDI-112. Frequency of use of primary drug of clients entering inpatient treatment, 2009 or most recent year available Part (ii) All opioid inpatient clients by country and frequency of use (%)
TDI TDI-112. Frequency of use of primary drug of clients entering inpatient treatment, 2009 or most recent year available Part (iii) New cannabis inpatient clients by country and frequency of use (%)
TDI TDI-112. Frequency of use of primary drug of clients entering inpatient treatment, 2009 or most recent year available Part (iv) All cannabis inpatient clients by country and frequency of use (%)
TDI TDI-112. Frequency of use of primary drug of clients entering inpatient treatment, 2009 or most recent year available Part (v) New stimulants (other than cocaine) inpatient clients by country and frequency of use (%)
TDI TDI-112. Frequency of use of primary drug of clients entering inpatient treatment, 2009 or most recent year available Part (vi) All stimulants (other than cocaine) inpatient clients by country and frequency of use (%)
TDI TDI-112. Frequency of use of primary drug of clients entering inpatient treatment, 2009 or most recent year available Part (vii) New cocaine (HCI and ‘crack’) inpatient clients by country and frequency of use (%)
TDI TDI-112. Frequency of use of primary drug of clients entering inpatient treatment, 2009 or most recent year available Part (viii) All cocaine (HCI and ‘crack’) inpatient clients by country and frequency of use (%)
TDI TDI-113. All clients entering treatment for opioids by country and type of opioid misused (%), 2007 or most recent year available
TDI TDI-114. Primary opioids distribution (percent) among all clients entering treatment by country and type of treatment centre (%), 2009
TDI TDI-115. HCL and crack use of clients entering outpatient treatment, 2009 or most recent year available Part (i) New outpatient clients by country and type of cocaine product
TDI TDI-115. HCL and crack use of clients entering outpatient treatment, 2009 or most recent year available Part (ii) All outpatient clients by country and type of cocaine product

Page last updated: Friday, 29 April 2011